RGEN vs SPY
Repligen Corporation (RGEN) versus SPDR S&P 500 ETF Trust (SPY) — a side-by-side from cached financials, not a winner call.
Repligen Corporation (RGEN) is a medical instruments & supplies company listed on NASDAQ.
SPDR S&P 500 ETF Trust (SPY) common stock listed on US.
Latest reported RGEN revenue for 2026-06-30 was $204.1M. Net income was $5.0M. Revenue was up 5.1% from 2026-03-31 to 2026-06-30. RGEN currently screens at market cap $7.43B and trailing P/E 143.1.
SPY does not have a complete income-statement cache yet.
RGEN currently screens at market cap $7.43B and trailing P/E 143.1. SPY currently screens at market cap $0.
Not investment advice. Open the RGEN and SPY stock pages for the full models.
Not investment advice.